Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery.

Détails

ID Serval
serval:BIB_9384CE54E90F
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery.
Périodique
Current protocols in pharmacology
Auteur⸱e⸱s
Civenni G., Carbone G.M., Catapano C.V.
ISSN
1934-8290 (Electronic)
ISSN-L
1934-8282
Statut éditorial
Publié
Date de publication
06/2018
Peer-reviewed
Oui
Volume
81
Numéro
1
Pages
e39
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Prostate cancer (PCa) is the most common malignant visceral neoplasm in males in Western countries. Despite progress made in the early treatment of localized malignancies, there remains a need for therapies effective against advanced forms of the disease. Genetically engineered mouse (GEM) models are valuable tools for addressing this issue, particularly in defining the cellular and molecular mechanisms responsible for tumor initiation and progression. While cell and tissue culture systems are important models for this purpose as well, they cannot recapitulate the complex interactions within heterotypic cells and the tumor microenvironment that are crucial in the initiation and progression of prostate tumors. Limitations of GEM models include resistance to developing invasive and metastatic tumors that resemble the advanced stages of human PCa. Nonetheless, because genetic models provide valuable information on the human condition that would otherwise be impossible to obtain, they are increasingly employed to identify molecular targets and to examine the efficacy of cancer therapeutics. The aim of this overview is to provide a brief but comprehensive summary of GEM models for PCa, with particular emphasis on the strengths and weaknesses of this experimental approach. © 2018 by John Wiley & Sons, Inc.
Mots-clé
Animals, Disease Models, Animal, Drug Discovery, Humans, Male, Mice, Transgenic, Prostate/anatomy & histology, Prostatic Neoplasms/drug therapy, cancer models, genetically engineered mice, pre-clinical models, prostate cancer
Pubmed
Création de la notice
15/04/2019 11:40
Dernière modification de la notice
20/08/2019 15:56
Données d'usage